Epidural Neurostimulation of Posterior Funiculi for the Treatment of Buerger’s Disease

Quiles, Lorena Vaquer; González, Lucrecia Blasco; Samper, Juan Asensio; Pérez, Vicente Luis Villanueva; Alarcón, María Dolores López; Ibáñez, J. De Andrés

doi:10.1111/j.1525-1403.2009.00203.x

Cited by 4 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study includes 3 cases of young patients in whom it was decided to implant the SCS system during the course of their first hospital admission, at the time of full-blown onset of the disease and coinciding with its diagnosis. Some studies 24 consider SCS as a treatment option in patients with Buerger disease.…”

Section: Effects Of Scs On Ischemic Limbsmentioning

confidence: 99%

Spinal Cord Stimulation for the Treatment of Buerger Disease

Fabregat-Cid

Villanueva²,

Asensio³

et al. 2011

The Clinical Journal of Pain

View full text Add to dashboard Cite

Spinal cord stimulation is an accepted therapy for the treatment of chronic ischemic pain and ulcer healing and to avoid amputation in patients with severe, nonrevascularisable peripheral occlusive arteriopathy, and specially in the subgroup of patients with Buerger disease. It should not only be considered as a last resort strategy for pain control, but as a valid therapeutic option to improve perfusion of the limbs in the initial stages of the disease, however larger studies still remain necessary.

show abstract

Section: Effects Of Scs On Ischemic Limbsmentioning

confidence: 99%

Spinal Cord Stimulation for the Treatment of Buerger Disease

Fabregat-Cid

Villanueva²,

Asensio³

et al. 2011

The Clinical Journal of Pain

View full text Add to dashboard Cite

show abstract

“…70 – 72 In the selected cases, spinal cord stimulation might improve not only pain control but also perfusion by inducing sympathicolysis and via antidrome mechanisms. 73 , 74 …”

Section: Analgesiamentioning

confidence: 99%

Buerger’s disease: providing integrated care

Klein-Weigel¹,

Volz²,

Zange³

2016

JMDH

View full text Add to dashboard Cite

Buerger’s disease, also known as thromboangiitis obliterans (TAO), is a segmental inflammatory disease affecting small- and medium-sized vessels, which is strongly associated with tobacco use. Although the etiology is still unknown, recent studies suggest an immunopathogenesis. Diagnosis is based on clinical and angiomorphologic criteria, including age, history of smoking, clinical presentation with distal extremity ischemia, and the absence of other risk factors for atherosclerosis, autoimmune disease, hypercoagulable states, or embolic disease. Until now, no causative therapy exists for TAO. The most important therapeutic intervention is smoking cessations and intravenous prostanoid infusions (iloprost). Furthermore, effective analgesia is crucial for the treatment of ischemic and neuropathic pain and might be expanded by spinal cord stimulation. Revascularization procedures do not play a major role in the treatment of TAO due to the distal localization of arterial occlusion. More recently, immunoadsorption has been introduced eliminating vasoconstrictive G-protein-coupled receptor and other autoantibodies. Cell-based therapies and treatment with bosentan were also advocated. Finally, a consequent prevention and treatment of wounds and infections are essential for the prevention of amputations. To achieve better clinical results, integrated care in multidisciplinary and trans-sectoral teams with emphasis on smoking cessation, pain control, wound management, and social care by professionals, social workers, and family members is necessary.

show abstract